Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022" report to their offering.

According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease.

As per the report Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022, the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.

The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.

Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Psoriasis: An Overview

4. Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Psoriasis
4.1.2 Increasing Awareness
4.1.3 Growing Geriatric Population
4.1.4 Rising Healthcare Expenditure
4.2 Challenges
4.2.1 Patent Cliff of Blockbuster Drugs
4.2.2 High Cost
4.3 Opportunities
4.3.1 Biologic Drugs Flaring Up Psoriasis Drugs Market
4.3.2 Incessant Launch of Novel Products

5. Global Psoriasis Drugs Market Outlook 2022

6. Market Segmentation by Type of Drug Molecule
6.1 Biologic Drugs
6.2 Small Molecule/Chemical Drugs

7. Market Segmentation by Route of Administration
7.1 Systemic
7.2 Topical

8. Market Segmentation by Mechanism of Action
8.1 TNF Inhibitors
8.2 Interleukin Blockers
8.3 Others

9. Market Segmentation by Geography
9.1 North America
9.2 Europe
9.3 Asia-Pacific

10. Trends & Developments
10.1 Interleukin Inhibitors Driving Psoriasis Drugs Market
10.2 TNF-alpha Blockers for the Treatment of Psoriasis

11. Mergers, Acquisitions & Collaborations

12. Pipeline Analysis

13. Porter's Five Forces Analysis

14. Key Players
14.1 AbbVie Inc.
14.2 Biocon
14.3 Pfizer Inc.
14.4 Novartis
14.5 Eli Lilly and Company
14.6 Celltrion Inc.
14.7 Celgene Corporation
14.8 Johnson & Johnson
14.9 Dr.Reddy's Laboratories
14.10 Amgen Inc.

For more information about this report visit http://www.researchandmarkets.com/research/d3d8zn/global_psoriasis

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Immune Disorders Drugs, Immune Disorders Drugs, Psoriasis Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.